Market Overview

UPDATE: Benchmark Raises PT to $20 on Exact Sciences Corporation Ahead of Top Line Data

Related EXAS
Benzinga's Top Upgrades, Downgrades For February 22, 2017
18 Biggest Mid-Day Gainers For Tuesday
Owlstone Medical Hopes To Breathe Life Into Cancer Diagnosis (Seeking Alpha)

Benchmark maintained Exact Sciences Corporation (NASDAQ: EXAS) with a Speculative Buy and raised the price target from $17.00 to $20.00.

Benchmnark noted, "Exact's Q4 update affirmed our expectation that pivotal top line colorectal cancer study data should be announced in March or April. These results are expected to support the third and final modular PMA filing seeking approval of a colon cancer and pre-cancer screening test. Based on prior tests demonstrating up to 98% cancer sensitivity, we believe there is a high likelihood this prospective study can demonstrate cancer sensitivity that exceeds the FDA's anticipated 85% threshold for approval."

Exact Sciences Corporation closed at $10.56 on Wednesday.

Latest Ratings for EXAS

Feb 2017Roth CapitalUpgradesNeutralBuy
Oct 2016JefferiesMaintainsBuy
Aug 2016Goldman SachsMaintainsNeutral

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Analyst Ratings


Related Articles (EXAS)

View Comments and Join the Discussion!